BIONTECH (BNTX.OQ) Trading
Live Chart & Price Analysis
View the real-time BIONTECH (BNTX.OQ) quote and decide if you want to go long or short. Find insights, analysis, the latest news and other information to help you with your trading.
$88.33
-0.46%Followers
3,009
Annual change
-14.82%
Daily price range:
Low
88.21
High
90.21
Trade BNTX
CFD trading involves risk
BNTX live price
Live Chart
Past performance is not a reliable indicator of future results.
Should you buy or sell BIONTECH right now?
Based on NAGA Sentiment¹, 100.00% are buying BIONTECH and 0.00% are selling BIONTECH right now. However, opening a long or short position now depends on your risk tolerance, investment horizon, and BIONTECH market outlook.
Selling
0.00%
100.00%
Buying
BIONTECH price analysis
The price of BIONTECH today, as of October 14, 2026, was $88.33. That's down -0.40% from last session's BIONTECH closing price. The BIONTECH price is declining this week. Compared to last week, the rate of BIONTECH is down -4.90%, and it's down -8.60% from one month ago.
The 52-week BIONTECH price high is $123.63, while the 52-week BIONTECH price low is $78.83.
Year to date, BIONTECH price is down -14.40% from the beginning of the year and has had a return of -14.40% in the last 12 months.
Low$88.21
Day's Range
Low$78.83
52w Range-1.0%
1h
-0.4%
24h
-4.9%
7d
-9.5%
14d
-8.6%
30d
-14.4%
1y
BIONTECH trading insights
The crowd feels NEGATIVE about BIONTECH, with a HIGH volume of news backing the NEGATIVE sentiment score². At the start of today's BIONTECH trading session, the sentiment signal³ is BEARISH, indicating whether the BIONTECH price is more likely to increase or decrease today and in the following days.
The level of news⁴ backing the sentiment score is HIGH, indicating how confident the markets are to buy BIONTECH right now. The LOW subjectivity⁵ indicates that the BIONTECH price is UNDERVALUED.
Sentiment Signal
Bearish
Next update: Oct 15, 12:30
Sentiment Score
Negative
31 / 100
Subjectivity
Low Subjectivity
24 / 100
Confidence Index
High
Discover key BIONTECH trends with NAGA Insights
What am I Missing?
Make informed decisions based on real-time data, expert analysis, and powerful research tools from TipRanks.
Access advanced BIONTECH charting, technical analysis, and live market data from TradingView.
Get AI-powered BIONTECH trade signals, in-depth market analysis, and technical strategy insights from Trading Central.
CFD trading involves risk
How to trade BIONTECH with leverage?
Trade BIONTECH if you want flexibility to speculate on its price movements in both directions. With CFDs, you can open a buy position (go long) if you think the BIONTECH price will rise, or you can open a sell position (go short) if you believe the BIONTECH price will fall.
You won’t need to commit to the full value of the position (see the required margin below), but bear in mind that leverage can increase both your profits and losses.
If you want to speculate on BIONTECH price, search for BIONTECH CFD. Then click on the "BIONTECH" symbol to view the chart and other insights before placing your trade. Also, review "BIONTECH" contract specification to be aware of all the BIONTECH CFD trading conditions.
trading conditions:
Platform
MT5
Platform spreads
Live: 0.6953
Ticker#BNTX.OQ
Margin (%)*
Volume step
Lot value
Minimum trade size
Maximum trade size
Commission0.00%
Monthly price change (%)-10.15%
Annual price change (%)-14.82%
Digits
Tick value0.009
Trading Hours & FeesCFD trading involves risk
About BIONTECH
BNTX
Biontech
CFD
-0.46%
$89.11
$88.33
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
BIONTECH price forecast, news, and analysis
Discover the latest news that can influence BIONTECH’s earnings sentiment and BIONTECH forecast and price predictions.
Positive
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), Arcus Biosciences (RCUS) and BioNTech SE (BNTX)
14/10/2026/09:50
Neutral
BioNTech Presses Ahead With BNT113 Cancer Trial After Initial Endpoint Miss
13/10/2026/16:35
FAQs about BIONTECH trading
The price of BIONTECH today, as of October 14, 2026, was 88.33. That's down -0.40% from the previous session's BIONTECH closing price.
IMPORTANT NOTICE: The content presented in the instrument page is only for informational, educational and support purposes. The material presented, including analyses, sentiment, consensus, prices, opinions or other content, is not an investment recommendation or information that recommends or suggests an investment strategy, nor is it included in the scope of investment advice. NAGA will not accept liability for any loss or damage, including but not limited to any loss of profits, that may arise directly or indirectly from the use of or reliance on the information contained in this page. NAGA is not responsible for the actions or omissions of the client, especially for the acquisition or disposal of financial instruments, made based on the information contained in this page. Past performance is not necessarily indicative of future results, and anyone acting on this information does so at their own risk. ¹ NAGA sentiment reflects the positions held by active NAGA users who currently maintain open trades in a specific instrument. This information is provided for indicative purposes only and should not be interpreted as investment advice or a recommendation to trade. ² ³ ⁴ ⁵ The sentiment dashboard is provided by Trading Central. Sentiment insights and market views are based on available data and do not guarantee future performance.
Need Help? Visit our Help Section
Download NAGA Trader
Download NAGA Trader
Click the QR code to enlarge
Copyright © 2026 – All rights reserved.
NAGA is a trademark of The NAGA Group AG, a German based FinTech company publicly listed on the Frankfurt Stock Exchange | WKN: A41YCM | ISIN: DE000A41YCM0.
The website is operated by JME Financial Services (Pty) Ltd an authorised Financial Services Provider, regulated by the Financial Sector Conduct Authority in South Africa under license no. 37166. JME Financial Services (Pty) Ltd is located at Suite 10, 21 Lighthouse Rd 201 Beacon Rock, Umhlanga Rocks, Kwa-Zulu Natal, 4320, South Africa.
JME Financial Services (Pty) Ltd acts as an intermediary between the investor and NAGA Capital Ltd, the counterparty to the contract for difference purchased by the Investor via Naga.com/za. NAGA Capital Ltd is authorised and regulated by the Financial Services Authority Seychelles (FSA) under licence No. SD026. NAGA Capital Ltd is the principal to the CFD purchased by investors on this website. Other group entities: NAGA Markets Europe LTD which is authorised and regulated by the Cyprus Securities and Exchange Commission (CySEC) under licence No. 204/13.
RISK WARNING: Derivatives are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how derivatives work and whether you can afford to take the high risk of losing your money. The value of financial products can increase as well as decrease over time, depending on the value of the underlying securities and market conditions. Illustrations, forecasts or hypothetical data are not guaranteed and are provided for illustrative purposes only. JME Financial Services (Pty) Ltd does not render advice in respect of the CFD’s offered on this website. Before making an investment decision, you should rely on your own assessment. The Company’s disclaimer, conflict of interest policy are available on legal documents section.